Post-Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 41954657.
- Also identified by DOI 10.1158/1078-0432.CCR-25-4702.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Accurate HER2 status assessment is crucial to identify patients with HER2-expressing tumors. In this post-hoc analysis of DESTINY-PanTumor02 (NCT04482309), we report concordance between local and central HER2 immunohistochemistry (IHC) results. This open-label, Phase 2 study evaluated trastuzumab deruxtecan (T-DXd; 5.4 mg/kg once every 3 weeks) for HER2-expressing (IHC 3+/2+ by local or central testing) locally advanced, unresectable or metastatic solid tumors after ≥1 systemic treatment or without alternative treatments. In total, 267 patients received T-DXd; 75.7% were enrolled based on local test result. Concordance between local and central HER2 test results was 58.6% for IHC 3+, 54.5% for IHC 2+, and 73.4% for IHC 3+ and IHC 2+ tumors combined. The moderate concordance observed between local and central IHC testing in DESTINY-PanTumor02 highlights the need for a validated diagnostic test and standardized algorithm for HER2 status assessment in solid tumors to ensure appropriate patient identification for HER2-directed therapies.